There are currently 45 active clinical trials seeking participants for Glioblastoma Multiforme research studies. The states with the highest number of trials for Glioblastoma Multiforme participants are California, Texas, New York and Ohio.
A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2
NCT03152318
Recruiting
This research study is evaluating an investigational drug, an oncolytic virus called rQNestin34.5v.2. This research study is a Phase I clinical trial, which tests the safety of an investigational drug and also tries to define the appropriate dose of the investigational drug as a possible treatment for this diagnosis of recurrent or progressive brain tumor.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/07/2025
Locations: Johns Hopkins University Medical Center, Baltimore, Maryland +4 locations
Conditions: Malignant Glioma of Brain, Astrocytoma, Malignant Astrocytoma, Oligodendroglioma, Anaplastic Oligodendroglioma of Brain (Diagnosis), Mixed Oligo-Astrocytoma, Ependymoma, Ganglioglioma, Pylocytic/Pylomyxoid Astrocytoma, Brain Tumor, Glioma, Brain Cancer, Glioblastoma, Glioblastoma Multiforme
Register for Updates
Loupe-Based Intraoperative Fluorescence Imaging
NCT04780009
Recruiting
Glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA) are the most common primary malignant brain tumors. Survival of patients with these brain tumors is directly related to the extent of resection. Consequently, a great deal of effort has been directed at developing techniques and technologies that allow more extensive, safe resections. This study will test a loupe-based wearable device in the clinical setting and compare its accuracy with a large operative microscope to identify tumor... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
07/03/2025
Locations: University of Kentucky, Lexington, Kentucky
Conditions: Glioblastoma Multiforme, Anaplastic Astrocytoma
Register for Updates
Subventricular Zone (SVZ) and Temozolomide in Glioblastoma Multiforme
NCT02177578
Recruiting
In this study patients will be treated with 6 weeks of radiation therapy plus temozolomide chemotherapy according to the standard of care. However, the radiation treatment plan will be modified to deliver an higher than routine radiation dose to the subventricular zone which is an area of the brain that contains stem cells that some scientists believe may contribute to glioblastoma recurrence. The purpose of the study is to see if the tumor is controlled for a longer period of time in patients t... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
06/30/2025
Locations: Sibley Memorial Hospital, Washington, District of Columbia +2 locations
Conditions: Glioblastoma Multiforme
Register for Updates
A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM
NCT05303467
Recruiting
The FRONTIER Study is a prospective, interventional, single-arm, multi-center, study to assess the safety and technical feasibility of TheraSphere GBM in patients with recurrent GBM.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/25/2025
Locations: University of California San Francisco, San Francisco, California +5 locations
Conditions: Glioblastoma Multiforme, Recurrent Glioblastoma
Register for Updates
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
NCT03175224
Recruiting
To assess: * efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CNS tumors harboring MET alterations, solid tumors harboring wild-type MET with overexpression of HGF and MET * efficacy of APL-101 as an add-on therapy to EGFR inhibitor for the treatment of NSCLC harboring EGFR activating mutations and developed acquired resis... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: Cedars-Sinai Medical Center - Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California +34 locations
Conditions: Advanced Cancer, Renal Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, NSCLC, Lung Cancer, Brain Tumor, Glioblastoma Multiforme, Solid Tumors, EGFR Gene Mutation, MET Amplification, HGF, Thyroid Cancer, Pancreatic Cancer, Colon Cancer, MET Alteration, MET Fusion, Exon 14 Skipping
Register for Updates
IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Adult Glioblastoma
NCT05353530
Recruiting
This is a phase I study to assess the safety and feasibility of IL-8 receptor modified patient-derived activated CD70 CAR T cell therapy in CD70+ adult glioblastoma
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/23/2025
Locations: University of Florida Health, Gainesville, Florida
Conditions: Glioblastoma, Glioblastoma Multiforme
Register for Updates
HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma
NCT04482933
Recruiting
This study is a clinical trial to assess the efficacy and confirm the safety of intratumoral inoculation of G207 (an experimental virus therapy) combined with a single 5 Gy dose of radiation in recurrent/progressive pediatric high-grade gliomas
Gender:
ALL
Ages:
Between 3 years and 21 years
Trial Updated:
06/23/2025
Locations: Holly Lindsay MD, Aurora, Colorado +4 locations
Conditions: Neoplasms, High Grade Glioma, Glioblastoma Multiforme, Malignant Glioma of Brain, Anaplastic Astrocytoma of Brain, High-grade Glioma, Anaplastic Glioma, Giant Cell Glioblastoma
Register for Updates
Atezolizumab and Pre-Surgical Brain Radiation Therapy for Glioblastoma Multiforme
NCT05423210
Recruiting
This is a single-arm pilot study that will recruit 12 patients with newly diagnosed Glioblastoma, a malignant brain tumor with a poor prognosis. Patients will be treated with fractionated stereotactic radiotherapy (FSRT) for 2 weeks, in addition to two doses of Atezolizumab (Tecentriq), an FDA approved PD- L1 inhibitor drug, 840 mg IV, at the beginning and at the end of the two-week time period, concomitantly with FSRT. After this initial two weeks treatment the patients will undergo craniotomy... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/19/2025
Locations: Stony Brook University Hospital, Stony Brook, New York
Conditions: Glioblastoma Multiforme
Register for Updates
Neurosurgical Neuronavigation Using Resting State MRI and Machine Learning
NCT05864976
Recruiting
This study is investigating the use of a computer algorithm to analyze scans of the brain before surgery to predict how a person's tumor will respond to treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/19/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Glioblastoma Multiforme
Register for Updates
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
NCT05879367
Recruiting
The purpose of this study is to establish the recommended phase 2 dose of eflornithine in combination with temozolomide in patients whose glioblastoma or astrocytoma is newly diagnosed, and to evaluate safety and tolerability of this combination at that dose.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/19/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +7 locations
Conditions: Glioblastoma, IDH-wildtype, Glioblastoma, Glioblastoma Multiforme, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, GBM, Astrocytoma, Astrocytoma, IDH-Mutant
Register for Updates
A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With Glioblastoma in Combination With Standard-of-care Treatment
NCT05708352
Recruiting
This is a Phase 2, randomized two-armed, multi-site study of 170 patients with newly diagnosed glioblastoma multiforme. Patients will be randomized 1:1 to receive Keto Diet, or Standard Anti-Cancer Diet. All patients will receive standard of care treatment for their glioblastoma. The Keto Diet intervention will be for an 18-week period and conducted by trained research dietitians. Daily ketone and glucose levels will be recorded to monitor Keto Diet adherence. This two-armed randomized multi-si... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2025
Locations: Cedars-Sinai Medical Center, Los Angeles, California +4 locations
Conditions: Glioblastoma Multiforme
Register for Updates
A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM
NCT03862430
Recruiting
This clinical trial is testing the safety and efficacy of NanO2TM administered via intravenous infusion in combination with standard radiation and chemotherapy. NanO2TM is being developed to increase the amount of oxygen delivered to tumors which is hoped to increase the effectiveness of radiation therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/10/2025
Locations: Center for Neurosciences, Tucson, Arizona +11 locations
Conditions: Glioblastoma Multiforme
Register for Updates